1. Introduction {#s0005}
===============

Hepatitis E virus (HEV) infection is being increasingly recognized in medical research as HEV infection has reached industrialized countries. Although HEV was discovered in 1983 ([@bb0020]) and subsequent experimental analyses were initiated since 1990/1991 on HEV isolates ([@bb0470]), there exists a considerable lack of understanding and knowledge of transmission routes, life-cycle, pathogenesis, genome variability and viral evolution.

Substantial epidemics and sporadic outbreaks of hepatitis E occur in tropical and sub-tropical countries (e.g., in India, Uganda, Sudan, and Mexico), with up to tens of thousands affected ([@bb0080], [@bb0235]). Approximately two billion people (one-third of the world population) live in areas endemic for HEV and are at risk ([@bb0415]). HEV infections are less frequently documented in industrialized countries, as it is believed to be associated with travel to HEV-endemic countries. However, by the end of the millennium, the numbers of autochthone cases were rising exponentially. HEV infections in Western Europe have been reported ([@bb0080], [@bb0235], [@bb0435]). Reasons for discrepancies of HEV presentation between developing and developed countries are diverse. The possible likelihood refers to the route of transmission and the different distribution of HEV genotypes ([@bb0410], [@bb0485]). In developing countries, HEV infection is transmitted mainly as waterborne/fecal-oral due to poor hygiene conditions, whereas in developed countries HEV is transmitted mainly foodborne due to zoonotic transmission by consumption of undercooked meat and bowels ([@bb0325]). In this regard, HEV is unique, as the only hepatitis virus with an animal reservoir.

HEV variants are viral factors that are known to be associated with transmission dynamics and pathogenicity ([@bb0235], [@bb0240], [@bb0285], [@bb0330]). HEV mutations occur under selective pressure imposed by the host immune system and by antivirals. HEV heterogeneity shall contribute towards HEV physiology, pathogenesis and transmission patterns ([@bb0295]). In this review, we aim to compile knowledge and discuss recent advances on the casual role of HEV heterogeneity and its variants on viral morphogenesis, pathogenesis, clinical relevance and antiviral resistance.

2. Clinical Course and Pathogenesis of HEV Infection {#s0010}
====================================================

Although the majority of HEV infections are asymptomatic, the clinical course of symptomatic infections includes acute and chronic hepatitis E, fulminant liver failure and extrahepatic symptoms ([@bb0090], [@bb0170]). Acute hepatitis E is usually defined as a self-limiting disease and lasts approximately 8 weeks and the symptoms are typically unspecific and mostly indistinguishable from other types of acute viral hepatitis ([@bb0555]). HEV-RNA can be detected in both serum and stool before the onset of clinical symptoms and lasts less than a month after symptom onset in serum but may persist longer in the stool ([@bb0270]). A severe form of acute hepatitis (fulminant hepatic failure) has been observed in patients with pre-existing liver diseases and in pregnant women ([@bb0070], [@bb0375]). The severity of HEV infection in pregnant women may be associated with the hormonal balance and immunologic complexity during pregnancy ([@bb0035], [@bb0375]). HEV replication occurring in the human placenta may lead to poor pregnant outcomes, including HEV transmission from mother to newborn and abortion ([@bb0040], [@bb0375]).

Chronic hepatitis E is defined by the persistence of HEV-RNA and/or *anti*-HEV IgM for more than six months with elevated alanine aminotransferase (ALT) levels. Chronic HEV infection has been reported primarily in immunocompromised individuals, in organ transplant recipients, patients under chemotherapy, and HIV-infected patients ([@bb0075], [@bb0225]). Chronic hepatitis E has been associated with the development of fibrosis and/or cirrhosis in patients with solid-organ-transplantation ([@bb0225]). Chronic HEV infection largely depends on the host immune responses, and thus the suppressed immunity in those specific groups of patients enables the virus to persist and establish chronic infection. The impairment of HEV-specific T-cell responses is likely associated with the development of chronic hepatitis E ([@bb0515]). However, rare cases of chronic and/or persistent HEV infection have also been reported in healthy, immunocompetent individuals ([@bb0150]).

HEV may also contribute to various extrahepatic manifestations, including pancreatitis, hematological disorders (thrombocytopenia and anemia), kidney disorders and neurological complications (Guillain-Barré syndrome and meningoencephalitis) ([@bb0500], [@bb0535], [@bb0555]). The discovery of HEV quasispecies in serum and cerebrospinal fluid additionally suggest a possible role in neurological disorders and relate to the emergence of neurotropic HEV variants ([@bb0230]). The extrahepatic manifestation mechanism can be explained by HEV replication in the extrahepatic tissues/organs and cause local tissue damage and inflammation. This is supported by recent findings, which showed HEV replication in the human placenta and neuronal-derived tissues ([@bb0040], [@bb0105]). Other mechanisms such as cross-reactive immune responses, generation of immune complexes, and secondary infections have been proposed ([@bb0125]). However, the exact underlying mechanism of extrahepatic manifestations by HEV warrants further investigation.

3. HEV Biology and Molecular Virology {#s0015}
=====================================

HEV is a small RNA, non-enveloped virus, 32--34 nm in diameter and belonging to the genus *Orthohepevirus* of the *Hepeviridae* family ([@bb0235]). The HEV genome is a positive-sense single-stranded RNA molecule of 7.2 kb containing three open reading frames (ORF1, ORF2, and ORF3), 5′- and 3′-untranslated regions (UTRs), and a polyA-tract at the 3′-end ([@bb0235]) ([Fig. 1](#f0005){ref-type="fig"}). ORF1 encodes the non-structural proteins and enzymes including methyltransferase (MeT), RNA helicase (Hel) and RNA-dependent RNA polymerase (RdRp) required for RNA replication. ORF2 expresses the capsid protein. ORF3 overlaps partially with ORF2 and encodes a multifunctional phosphoprotein that can modulate cellular signaling and is related to particle secretion ([@bb0400]). A novel ORF4 of 158 amino acids within ORF1 has been described recently for HEV-1. ORF4 is involved in HEV replication by interacting with multiple viral proteins (helicase, RdRp and X) and host factors such as eEF1α1 (eukaryotic elongation factor 1 isoform-1) and β-tubulin ([@bb0370]). However, the presence and functional role of ORF4 in other HEV genotypes need to be explored. Additionally, two *cis*-reactive elements (CRE) located at the junction (between ORF1 and ORF3) and at the 3′-end of the ORF2 and 3′-UTR are essential for HEV replication and promoter activity for the subgenomic viral RNA ([@bb0115]).

Although the HEV life-cycle relates to other ssRNA viruses, it warrants further investigation ([Fig. 2](#f0010){ref-type="fig"}). HEV attaches the cells via the interaction of ORF2 with attachment receptors such as heparan sulfate proteoglycans (HSPGs) and heat shock cognate protein 70 (HSC70) and enters the cells through dynamin-2, clathrin, membrane cholesterol and actin dependent endocytosis ([@bb0180], [@bb0220]). After entry, the virion uncoats and releases the viral RNA into the cytoplasm. The virus utilizes the host translation machinery to translate the ORF1 polyproteins which include viral enzymes. The viral genomes are replicated by the viral RNA helicase and RdRp, the ORF2 and ORF3 proteins are also translated from the viral subgenomic RNA ([@bb0090]). The replication complex of HEV is likely positioned at the ER-Golgi intermediate compartment, where the viral proteins and positive single-stranded RNA could be localized ([@bb0430], [@bb0465]). The assembly of RNA and ORF2 protein forms the progeny viral particles, which are then released from the host cells through the endosomal sorting complexes required for transport (ESCRT) machinery. The interaction of the conserved PSAP motifs in the viral ORF3 protein with the tumor susceptibility gene 101 (*TSG101*) (a component of the ESCRT machinery) is likely essential for the maturation and egress of HEV ([@bb0360], [@bb0365]) ([Fig. 2](#f0010){ref-type="fig"}).

4. Genetic Variability of HEV and Clinical Implication {#s0020}
======================================================

Seven HEV genotypes are recognized within the *Orthohepevirus A* species based on the phylogeny of entire viral genomes (HEV-1 to HEV-7) ([@bb0510]). Four HEV genotypes (HEV-1 to HEV-4) are well recognized as human pathogens while HEV-5 and HEV-6 are identified only in animals so far (wild boars) ([@bb0505]). Recently, the camelid HEV-7 has been reported to infect human and cause chronic hepatitis E, as observed in a liver transplanted patient ([@bb0285]). The human pathogenic prototype strains include HEV-1, HEV-2, HEV-3, HEV-4, and of HEV-7 ([@bb0235], [@bb0240], [@bb0330]). Four major human pathogenic HEV genotypes have been further classified into 24 sub-genotypes including five HEV-1 sub-genotypes (1a to 1e), two HEV-2 sub-genotypes (2a and 2b), ten HEV-3 sub-genotypes (3a to 3j) and seven HEV-4 sub-genotypes (4a to 4g) ([@bb0320]). However, the sub-classification of HEV genotypes is controversial, because of missing valid data and an inadequate number of reference strains available for the various sub-genotypes.

The HEV genotypes have different reservoirs, and distinct distribution and transmission patterns. HEV-1 is frequently distributed in Asia, HEV-2 in Africa and Mexico, HEV-7 in the Middle East, whereas HEV3 and HEV4 are distributed throughout the world ([@bb0235], [@bb0285], [@bb0455]). HEV-1 and HEV-2 exclusively infect humans, whereas HEV-3 and HEV-4 are more permissive with a wider host range (especially swine, wild boar, rabbits, deer, and humans) ([@bb0235], [@bb0240], [@bb0330]). HEV-7 can infect both camels and humans ([@bb0285]). Zoonotic HEV has potential to cause fatal disease in infected patients and may become more transmissible among humans ([@bb0005]). HEV-1 and HEV-2 are mainly transmitted through the waterborne/fecal-oral route and are responsible for large waterborne outbreaks and epidemics in developing countries, whereas HEV-3, HEV-4 and HEV-7 are associated with zoonotic transmission and cause sporadic infections in developed countries ([@bb0235], [@bb0240], [@bb0285], [@bb0330]).

The HEV genotypes are believed to be associated with the clinical course of the symptomatic infections. HEV-1 and HEV-2 mainly contribute to severe acute hepatitis but not towards chronic HEV infection ([@bb0005], [@bb0270]). Infections with HEV-3, HEV-4 and HEV-7 do not only cause acute hepatitis but can also lead to chronic hepatitis in immunocompromised patients ([@bb0135], [@bb0140], [@bb0285], [@bb0475]). Patients infected with HEV-4 had more severe outcomes compared to those infected with HEV-3 ([@bb0345]). Infection with HEV-1 but not with HEV-3 and HEV-4 was associated with severe forms of liver disease and complications in pregnant women ([@bb0270], [@bb0275]). In addition, infection with HEV-3 has been shown to cause fulminant liver failure in patients with pre-existing liver diseases ([@bb0070], [@bb0420]). These data indicate that HEV variability contributes significantly to the pathogenesis and severity of HEV infection.

HEV heterogeneity of the polyproline region (PPR) and macro domain (X-domain) have been characterized in eight immunocompromised patients with HEV persistence and six with resolving infections. The diverse complexity of nucleotides and amino acids (aa) in both the PPR and macro domain of ORF1 is higher in patients with chronic HEV infections than those with resolving infections ([@bb0295]). Selection pressure of the host immune response during acute infection may be a possible reason for this diverse complexity. This suggests that the genetic heterogeneity enables the virus to better adapt to the host and persist longer, and thus establish chronicity.

5. Recombination of HEV {#s0025}
=======================

Recombination events of HEV occur within seven defined HEV genotypes and also between human and HEV strains ([@bb0505]). Recombination events were frequently distributed in the X- and helicase domains of ORF1 ([@bb0550]). Notably, HEV strain with ORF1 rearrangement (derived from a chronically infected patient) can efficiently adapt in cell culture ([@bb0215]). Insertion and deletions were reported in the hypervariable domain (polyproline region; HVR/PPR) of ORF1. A 171-nucleotide insertion encoding a 58 aa fragment of the human *RPS17* gene (ribosomal protein S17) ([@bb0495]) and a 174 bp insertion of *RPS17* (detected in a chronically infected HEV patient) were associated with an increased HEV replication in hepatoma cells ([@bb0260], [@bb0495]). A recent study characterized the PPR of the HEV genome in 27 immunocompromised patients with HEV persistence and 32 with resolving infections. Of the 27 strains isolated from patients with HEV persistence, the recombination occurred in three HEV strains over the infection period ([@bb0300]). Recombination events increase the likelihood of genetic variability and thus diverse pathogenesis with a prospective potential for chronification of HEV infection ([@bb0380]). In addition, two fragments of human origin (inter-α-trypsin inhibitor-*ITI*, and tyrosine aminotransferase-*TAT*) were found to be inserted in the PPR. Those inserted fragments enhanced the HEV replication, probably by providing a new potential regulatory site ([@bb0300]).

6. HEV Mutations and Their Functional Role {#s0030}
==========================================

RNA viruses exhibit high genetic variability by rapid evolution with estimated mutation rate ranging from 10^− 6^ to 10^− 4^ substitutions per nucleotide per strand copying ([@bb0480]). The HEV mutation rates were estimated indirectly from clinical isolates as 1.5 base substitutions per site per year and were similar to those reported for hepatitis C viruses ([@bb0525]). Mutations can occur frequently over the entire HEV genome during propagation and consecutive passages for adaptation to cell culture ([@bb0315]). High variability and frequent selection of mutations in the HEV genome is due to the transcription process. The viral RdRp, which lacks the proof-reading ability of DNA polymerases, likely increases the variations in the HEV genome. On the other hand, the selection pressure imposed by antiviral drugs and host immune responses may additionally contribute to increased HEV variability ([@bb0295]). Although a quasispecies is linked to mutations, not all mutations in the viral genome shall generate viable virus quasispecies ([@bb0280]).

6.1. Mutations in the ORF1 Region {#s0035}
---------------------------------

ORF1 encodes several non-structural proteins required for HEV replication and protein processing including MeT, papain-like cysteine protease (PCP), Hel, and PdRp activities ([Fig. 1](#f0005){ref-type="fig"}). ORF1 also contains several functional domains namely the Y-domain, HVR and macro domain (X-domain), which show homologies to other positive-stranded RNA viruses ([@bb0045], [@bb0265]). MeT is responsible for capping the 5′-end of the viral pregenomic RNA, which is critical for viral infection ([@bb0115]). In the capping process, Hel is involved in phosphatase activity that catalyzes the initial cap formation. The Hel-domain also possesses RNA duplex unwinding activities ([@bb0250], [@bb0255]).

Although the PCP has been predicted within the ORF1 polyprotein by a computer-assisted analysis ([@bb0265]), the function of the protease activity is unclear. By constructing a series of HEV replicons harboring numerous mutations in the PCP region and followed by in vitro analyses, nine aa substitutions (H443L, C457A, C459A, C471A, C472A, C481A, C483A, H497L and H590L) were associated with complete suppression of HEV replication ([@bb0385]). A catalytic dyad (C434--H443) and bivalent metal-binding motifs (C457--H458--C459 and C481--C483) were essential for HEV protease structural-integrity ([@bb0405]). These results indicate that protease activity is essential for HEV replication and mutations in the PCP region may affect HEV protease activity by modifying the enzyme structure ([Table 1](#t0005){ref-type="table"}).

The HVR domain overlaps PPR between the PCP and X-domain (Macro-D) and contributes to viral replication efficiency and adaptation ([@bb0440], [@bb0445], [@bb0450]). HVR varies in length among HEV strains and genotypes, shows sequence heterogeneities, and can tolerate small deletions and insertions ([@bb0440]). The variation in length of the HVR domain is associated with HEV attenuation ([@bb0440]). Consistently, the deletions in the N-terminal and central regions of the HVR domain have significant effect while deletion in the C-terminal region has a relatively lesser impact on the replication efficiency. Furthermore, complete HVR deletion of the avian HEV eliminates virus infectivity, but not viral replication in vivo ([@bb0445]). These findings indicate that the HVR domain is not essential for viral replication, but has a role in HEV infectivity. The HVR domain may involve virus entry and assembly by interacting with other viral and host factors. A 282 bp-insertion (duplicated 258 bp HVR-derived and 24 bp RdRp-derived fragments) in the HVR domain of an isolate from patient with chronic hepatitis E was associated with increased viral replication. Particularly, the 24 bp RdRp-derived insertion contributed to viral replication ([@bb0095]). Therefore, the deletion/insertion or recombination events occurring in HVR may be associated with HEV pathogenesis and thus clinical outcome.

The X-domain is involved in ADP-ribose metabolism and posttranslational modifications and is homologous to other pathogens ([@bb0175]). However, X-domain function in HEV physiology is poorly characterized. The macro domain could recruit poly (ADP-ribose)-modified cellular factors and might have an impact on HEV replication ([@bb0110]). A highly conserved 'glycine-triad' comprised of three aa substitutions G815V, G816V and G817V in the downstream X-domain was identified and two of those (G816V and G817V) resulted in the complete suppression of HEV replication ([@bb0385]). Six HEV replicons harboring the aa substitutions N806A, N809A, H812L, G815A, G816A and G817A were constructed to characterize the functional role of the X-domain. The results revealed that the mutations N809A, H812L, G816A/V and G817A/V lead to a complete abrogation of HEV replication ([@bb0390]). These findings indicate the critical role of X-domain in regulation of HEV physiology and mutations in this domain completely damage HEV replication ([Table 1](#t0005){ref-type="table"}).

Viral helicase activity is critical for HEV replication and specific mutations in the Hel region can stop helicase activity ([@bb0250], [@bb0255]). The amino acid substitutions in the Hel domain (L1110F and V1120I) are frequently detected in HEV-1 isolates derived from patients with fulminant hepatic failure ([@bb0100]). These distinct mutants were shown to influence ATPase activity but not the RNA duplex unwinding activity of the helicase enzyme. Notably, HEV mutant replicons with the single mutation (L1110F or V1120I) and the double mutation (L1110F/V1120I) showed a significant decrease in viral replication in comparison to wild-type HEV ([@bb0100]). In addition, artificial deletions in the Hel domain (motifs Ia and III) significantly impaired ATPase and unwinding activities of the helicase enzyme ([@bb0335]). These findings indicate that the negative regulation of helicase activity by these non-synonymous substitutions (L1110F or V1120I) and deletions (motifs Ia and III) in the Hel domain are associated with reduced HEV replication ([Table 1](#t0005){ref-type="table"}).

The RdRp domain contains eight conserved motifs that are closely homologous to RdRps of other positive-stranded RNA viruses such as hepatitis C virus ([@bb0010]). The RdRp replicates the HEV genome through an anti-genomic RNA intermediate and the RdRp activity could be localized to the endoplasmic reticulum ([@bb0465]). Several HEV mutations namely Y1320H, K1383N, D1384G, K1398R, V1479I, Y1587F and G1634R have been identified in patient-derived HEV isolates. These mutations were demonstrated in vitro to associate with HEV replication fitness ([@bb0085], [@bb0095], [@bb0540]). The findings indicate that the mutations occurring in the RdRp domain can affect the HEV replication by modulating the RdRp activity ([Table 1](#t0005){ref-type="table"}).

6.2. Mutations in the ORF2 Region {#s0040}
---------------------------------

ORF2 encodes the viral capsid protein, which assembles after glycosylation and encapsidation of the viral genomic RNA into the infectious viral particles ([@bb0205]). The capsid protein is immunogenic since neutralizing antibodies effectively target conformational epitopes at the P-domain ([@bb0585]) ([Fig. 1](#f0005){ref-type="fig"}). Besides structural properties, HEV capsid protein is involved in host cell interaction by a potential ER localization signal ([@bb0205]). ORF2 contributes to virus-host interaction as ORF2 revealed modulatory effects on eIF2a, ATF-4, Hsp72, NFkB, and activation of the CHOP promoter ([@bb0210], [@bb0520]). Interactions of capsid proteins with host factors (Grp78/BiP, α-tubulin, and Hsp90) are necessary for virus attachment, uptake, and trafficking ([@bb0580]). The C-terminal 52 aa (C52aa) domain of the capsid protein is required to promote accurate encapsidation and stabilize encapsidated viral particles ([@bb0490]).

Three mutations (T5338C, A5362G, and C6356T) resulted in aa changes (F51L, T59A, and S390L, respectively) and a deleterious point mutation A756 resulted in a downstream frame-shift of the *ORF1* gene have been identified in ORF2 ([@bb0185]). These mutations occur naturally under selective immune pressure and may influence the viral protein function thus contribute to a decreased HEV replication and infectivity ([@bb0185]). Although ORF2 production was not significantly affected by these mutations (F51L, T59A, and S390L), the F51L mutation partially contributed to virus attenuation and the T59A and S390L mutations resulted in a more drastic HEV attenuation ([@bb0065]). In this regard, the F51L and T59A mutations may affect viral genomic RNA packaging, and the S390L mutation may prevent the interaction between virus and host cell receptor by changing the structure of antigenic epitopes ([@bb0065]).

The non-synonymous substitutions at aa-positions 137, 310 and 311 (especially Asn to Gln) prevent glycosylation of corresponding sites in the glycosylation motif of HEV capsid protein. These mutations do not significantly affect either the viral replication or capsid protein synthesis. However, they eliminate HEV infectivity by preventing the formation of HEV particles. Although the mutation N562Q does not stop HEV morphogenesis, it rather affects the dimerization of the ORF2 protein and the infectivity of the newly synthesized HEV particles ([@bb0165]). The substitutions N562Q/D/P/Y were further verified to evolve in glycosylation, dimerization and especially in the activity of neutralizing epitopes of the capsid protein ([@bb0565]). Recently described substitutions in ORF2 L477T and L613T (HEV-4) and V606A (HEV-1) were associated with HEV immunoreactivity by affecting the neutralization epitope ([@bb0310], [@bb0570]). These findings indicate that the ORF2 protein structure is critical for HEV replication, infectivity, and immunoreactivity ([Table 1](#t0005){ref-type="table"}). The ORF2 non-synonymous substitutions resulting in an alteration of epitope structure may facilitate HEV to adapt and/or escape successfully the host immune response, which can lead to chronicity ([@bb0540]). Under host immune pressure, HEV mutations in ORF2 may involve in modulation of HEV immunoreactivity, which is related to outcomes and progression of liver disease ([@bb0515]).

6.3. Mutations in the ORF3 Region {#s0045}
---------------------------------

The ORF3 encodes a small phosphoprotein of 114 amino acids (HEV-1, -2 and -4) or 113 amino acids (HEV-3) that is translated from the 2.2 kb sgRNA. ORF3 is essential to promote cell survival and proliferation, modulation of the immune responses in the acute phase, and in immune-suppression ([@bb0045]). The ORF3 protein is required for regulation of HEV replication and infectivity and is a multifunctional, pleiotropic protein, and interacts with host cellular signaling ([@bb0055], [@bb0355]). Therefore, ORF3 expression may have a pivotal effect on HEV pathogenicity. ORF3 interacts with ORF2 in a phosphorylation-dependent manner and the 25-aa region (residues 57--81), especially the phosphorylation at the position S80 of ORF3, is responsible for the ORF2--ORF3 interaction ([@bb0545]). The mutation S80A (but not S80L, which does not change aa in ORF2) is associated with abolishment of HEV infectivity. However, ORF3 phosphorylation at position S80 is not required for viral replication and infectivity ([@bb0155]). Due to the overlapping of ORF2 and ORF3, the ORF3 S80A mutation also corresponds to the V66G aa substitution in ORF2 ([@bb0155]). The S80A mutation therefore may affect the ORF3 regulation during HEV assembly by either an unknown mechanism or by influencing the ORF2--ORF3 interaction through modifying the structure of both ORF2 and ORF3. In addition, two conserved PSAP motifs have been identified to residues aa 86--89 and aa 95--98 of ORF3. Mutations in these motifs were associated with decreased HEV replication ([@bb0360]) ([Table 1](#t0005){ref-type="table"}).

Mutations in the ORF3 and ORF2--ORF3 overlapping regions are associated with the production of ORF2 and ORF3 proteins ([@bb0155]). The mutations A5145C, A5178C, A5190C, G5676T and T5690G stop the ORF2 expression (but not ORF3) while the mutation CGC5148--5150AGA eliminates ORF3 production (but not ORF2). The mutations A5108Δ, T5109C, C5112U, TCT5116--5118AGC and T5121C damage the expression of both ORF2 and ORF3. These mutations eliminating ORF3 production are associated with HEV infectivity in an animal model system ([@bb0155]) ([Table 1](#t0005){ref-type="table"}). Furthermore, the interaction of ORF3 protein with various host factors deactivates the ORF3 protein function that may subsequently eliminate viral replication and infectivity ([@bb0350], [@bb0355]). The highly dynamic activity of ORF3 protein in interaction with host factors may lead to stimulation and enhancement of the host immune response that enables the host to clear the virus more rapidly. This may provide an explanation for the self-limitation and a short period of HEV persistence during clinical course. In addition, mutations in the ORF3 protein may modulate its binding capacity to the host proteins that results in a complexity of immune response and clinical outcomes. However, more studies are required to clarify this hypothesis.

6.4. Mutations in the Junction and *cis*-Reactive Elements (CRE) {#s0050}
----------------------------------------------------------------

The junction region located between the end of ORF1 and beginning of ORF3 was predicted to contain a highly conserved stem-loop (SL) structure ([@bb0050]) ([Fig. 1](#f0005){ref-type="fig"}). A point mutation at the third in-frame AUG in the junction region, which is the exact start position for ORF3 translation, completely stops virus infectivity ([@bb0190]). An increased number of mutations in the loop, especially at the AGA motif, is associated with reduced HEV replication, and mutation on the stem of the sub-genome start sequence leads to an inhibition of HEV replication ([@bb0050]). The sequence and structure of the junction region play an important role in HEV replication while mutations occurring at the third in-frame AUG in the junction region may inhibit the ORF3 production. However, the precise mechanism of how the junction region influences the HEV replication is unclear.

Two CREs have been identified in HEV; the first CRE is located at the 3′-end of ORF2 ([@bb0115]) and the second CRE is located in the ORF1--ORF3 intergenic junction region of the HEV genome, which may be essential for HEV replication and important for ORF2 and ORF3 expressions ([@bb0155]) ([Fig. 1](#f0005){ref-type="fig"}). The mutations identified in the first CRE (G5101U, U5100C, C5117G, U5118G), which form the "lower-stem" structure of CRE, affect HEV replication and are associated with reduced HEV infectivity ([@bb0395]). A functional RNA element with two highly conserved stem-loop structures (ISL1 and ISL2) within ORF2 and 19 silent mutations were identified to disrupt the stem-loop structures and abolish capsid protein synthesis ([@bb0120]). The mutations G6574C, C6570G, G7106T/A, G7097A and C7144A are also associated with HEV attenuation by disrupting the predicted stem-loop structures of HEV-RNA molecule ([@bb0115], [@bb0120], [@bb0160]) ([Table 1](#t0005){ref-type="table"}).

7. HEV Mutations and Clinical Relevance {#s0055}
=======================================

An in-frame deletion of 246 bp in ORF3 of Indian HEV strain isolated from clinical samples has been reported, however, the functional and clinical relevance of this deletion were unknown ([@bb0460]). An analysis of 22 HEV-4 full-length sequences from patients with fulminant and acute hepatitis found that the substitutions at the positions C1816 and U3148 were significantly associated with fulminant hepatitis ([@bb0195]). However, only the mutation U3148 was confirmed to be associated with fulminant hepatitis by an additional analysis of 16 HEV-4 isolates. Further analysis of 86 HEV isolates showed that the U3148 variant revealed a stronger association with fulminant hepatitis in comparison to other variants (C3148 or G3148), and was associated with lower prothrombin activity ([@bb0195]). A comparable study extended the results using 28 HEV-4 full-length sequences (from fulminant and acute hepatitis) and identified the C5907 variant most significantly associated with fulminant hepatitis ([@bb0200]). An additive effect of both U3148 and C5907 mutations on fulminant hepatitis development was confirmed by further analysis of full-length sequences of 28 HEV-4 and 11 HEV-3 isolates as well as 35 partial sequences ([@bb0200]). However, the mechanism of how U3148 and C5907 mutations influence hepatitis E progression is unresolved as these mutations are silent substitutions not changing the aa ([Table 2](#t0010){ref-type="table"}).

The ORF1 mutation V1213A corresponding to the aa substitution V239A in the Hel domain was found in all patients with more severe hepatitis but not in the patient with mild clinical course indicating that the V239A mutation can be associated with increased virulence ([@bb0530]). Notably, the V239A substitution in the Hel domain may enhance helicase activity and subsequently increase HEV replication ([@bb0015]). Six aa changes in HEV-1 ORF1 including T563C (aa F179S), G977A (A317T), C2232T (T735I), T3355C (L1110F), G3386A (V1120I), and T4344A (F1439Y), were identified to be significantly associated with fulminant hepatic failure ([@bb0340]). A total of 22 nucleotide substitutions were identified in the ORF1 region of 55 HEV sequences obtained from patients with acute viral hepatitis and those with acute liver failure. Most of these mutations including two non-synonymous substitutions C4476G (C1483W) and A4616C (N1530T) in the RdRp were found only in the HEV sequences from acute liver failure patients ([@bb0030]). The mutations C1483W and N1530T were significantly associated with high viral load, abnormal prothrombin time, high bilirubin, and high mortality ([@bb0030]). The association of HEV mutations in ORF2 with disease severity was investigated. Six substitutions including C5927T, C5933T, T6014C, C6032T, G6098A, C6104T, and a novel amino acid mutation P259S in ORF2 were identified to be significantly associated with fulminant liver failure ([@bb0025]). These results indicate that non-synonymous substitutions can be associated with virulence and may affect viral replication (mutations in the RdRp) and especially enhance host immune response via modifying the antigen epitopes (non-silent mutations in ORF2 region) ([Table 2](#t0010){ref-type="table"}). The abundance of mutations in the HEV genome from patient isolates is probably due to selective immune pressure. These mutations enable the virus to better adapt and modulate the host immune responses that lead to severity of complications.

8. HEV Mutations and Vaccination {#s0060}
================================

Prevention of HEV infection in endemic areas is based on the implementation of appropriate hygiene and sanitary measures to avoid fecal-oral transmission. In regions where HEV infection is sporadic, the consumption of raw food should be avoided. HEV infection can be prevented with effective HEV vaccines and ORF2 is widely used as a target for vaccine development ([@bb0575]). Mutations in ORF2 may lead to a failure of an adaptive cellular immune response in vaccinated individuals. Therefore, mutations occurring in ORF2 sensitively affecting the ORF2 protein structure is one of the challenges for the protective efficiency of HEV vaccine programs. On the other hand, a number of mutations resulting in HEV attenuation (e.g., F51L, T59A, S390L, N562Q/D/P/Y, L477T, L613T and HVR deletion) may provide a basis for the development of live-attenuated vaccines against HEV ([@bb0065], [@bb0440], [@bb0570]). A strategy for viral attenuation and vaccine development has been proposed based on mutating the conserved active site lysine residue to arginine of the viral RdRp ([@bb0560]). Therefore, HEV mutations in the RdRp domain and deletions in the HVR domain have repercussions for the development of live, attenuated HEV vaccines.

9. Clinical Relevance of HEV Mutations in Antiviral Therapy {#s0065}
===========================================================

Although no HEV-specific treatment options show significant antiviral activity, the effectiveness of PEG-interferon-α in combination with ribavirin, and ribavirin alone for HEV infection have been recently documented ([@bb0245], [@bb0425], [@bb0555]). However, ribavirin treatment failure was reported in patients with chronic hepatitis E ([@bb0085], [@bb0095], [@bb0145], [@bb0305], [@bb0540]) ([Table 2](#t0010){ref-type="table"}). The entire HEV sequences before, during and after treatment courses were compared and a nucleotide substitution (G \> A) resulting in a G1634R mutation in the C-terminal region of the HEV-3 RdRp was identified ([@bb0085]). Although showing no effect on ribavirin resistance, the variants 1634R and 1634K significantly contribute to an increased efficiency of viral replication and infectivity compared to the wild-type G1634 ([@bb0085]). Comparable results confirmed a similar role for HEV-1 ([@bb0085]). This result was further supported by a clinical observation that plasma HEV-RNA levels were significantly increased in patients infected with 1634R mutant compared to non-1634R mutant viruses ([@bb0305]). These findings suggest that G1634R/K may not be a direct antiviral resistance mutation but partially involved in ribavirin treatment failure by enhancing HEV replication. By analyzing 63 HEV sequences from solid-organ transplant patients with chronic hepatitis E, the prevalence of the G1634R mutation was shown to be higher in non-sustained virologic response (SVR) compared to SVR patients ([@bb0305]). This observation is supported by evidence that the proportion of the G1634R mutation was rapidly increasing in patients with ribavirin treatment failure ([@bb0385], [@bb0565]). Antiviral resistance mutations (G1634R/K) can occur in HEV genome under ribavirin treatment, since ribavirin has been recently demonstrated to cause mutations in the HEV genome as well as in other RNA viruses ([@bb0095]). Ribavirin therapy can lead to an increased HEV variability (ORF1, ORF2 and ORF3) over time, especially in the RdRp domain ([@bb0540]). However, the presence of the 1634R mutation neither leads to absolute ribavirin resistance nor influences the response to re-treatment with ribavirin ([@bb0130], [@bb0305]). This result is in line with a finding showing that the ribavirin treatment failure is not directly caused by the G1634R mutation ([@bb0085]).

Besides the described G1634R mutation, two other substitutions (Y1320H, K1383N) in the RdRp domain, as well as two mutations (A723V, A647T) and a 282 bp-insertion (a duplicated 258 bp HVR-derived and a 24 bp RdRp-derived fragments) in the HVR were identified. Notably, the frequency of these substitutions (Y1320H, K1383N, G1634R and A723V) increased during the course of ribavirin treatment ([@bb0095]). The G1634R and Y1320H mutations enhanced viral replication but did not affect ribavirin susceptibility, whereas the K1383N mutation abrogated viral replication and was associated with increased ribavirin sensitivity by affecting the binding activity of the RdRp domain to guanosine-5′-triphosphate (GTP) ([@bb0095]). Although Y1320H and G1634R/K can compensate for the harmful effect on viral replication caused by the K1383N mutation ([@bb0095]), the interaction among these mutations and their functional role is yet to be understood. The A723V mutation had no effect on viral replication whereas the 282 bp-insertion in the HVR significantly increases viral replication. However, the artificial insertion and deletion of the 24 bp RdRp-derived fragment reduced viral replication compared to wild-type HEV, suggesting a role of the insertion and also other unknown factors ([@bb0095]). In addition, four additional substitutions (D1384G, K1398R, V1479I and Y1587F) together with the known mutations K1383N and G1634R in ORF1 were identified. Of those, the mutation G1634R could be detected in low frequencies before ribavirin therapy ([@bb0540]). These additional mutations (D1384G, K1398R, V1479I and Y1587F) were associated with increased ribavirin sensitivity, and with higher HEV replication ([@bb0540]).

The recent findings clearly demonstrate the mutagenic effect of ribavirin on the HEV genome, which can lead to an emergence of distinct viral populations ([@bb0085], [@bb0095], [@bb0145], [@bb0540]). These distinct viral populations resulted from ribavirin treatment failure may cause a more complicated clinical outcome, extrahepatic manifestations and may have different transmission patterns. Development of a new antiviral therapy or/and combination with an alternative therapeutic option (eg. PegIFNα, Sofosbuvir) may help to increase the efficiency of treatment course and to reduce the treatment failure risk as well as to avoid the emergence of the viral populations associated with drug resistance and fulminant liver failure. Investigating potential HEV mutations related to resistance to new antiviral therapies are recommended. In clinical practice, systematic examination of HEV genome variants by next-generation sequencing should be considered for any clinical relevance, which may associate with treatment failure, chronic and fulminant infections to predict therapy outcomes and in the progression of liver diseases.

10. Conclusions and Perspectives {#s0070}
================================

Although HEV infection is largely controlled by host immune responses, viral factors including HEV genetic variability associate with the clinical course, host adaption, and antiviral resistances. Different HEV genotypes exhibit a selective host range with unique transmission patterns and pathogenesis. Deletion/insertion, recombination and substitutions occurring in the HEV genome can influence HEV replication and virus-host interaction, and be subsequently associated to pathogenesis ([Table 1](#t0005){ref-type="table"} and [Fig. 2](#f0010){ref-type="fig"}). Under host immune pressure, clinically relevant non-synonymous and silent mutations occurring throughout the entire HEV genome may be associated with severe forms of the disease and potentially *anti*-viral resistances ([Table 2](#t0010){ref-type="table"} and [Fig. 2](#f0010){ref-type="fig"}). Ribavirin treatment failure is associated with the RdRp mutations Y1320H, K1383N, D1384G, K1398R, V1479I, Y1587F and G1634R. The mutations Y1320H and G1634R contribute to decreased susceptibility to antiviral drugs by enhancing HEV replication and infectivity, whereas the other mutations (eg. K1383N) likely reduce viral replication and increases ribavirin sensitivity. These mutations may affect the efficiency of viral RdRp activity; however, the precise role of these identified mutations remains unclear. Except for the drug resistance-related HEV mutations in the RdRp domain, most mutations in other regions found in clinical isolates do not corroborate with results from artificial mutations in functional studies, thus suggesting the nature of mutational complexity. Further studies will help to elucidate the possible contribution of HEV variants in HEV physiology, pathogenesis and clinical relevance.
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![Schematic description of the HEV genome and viral proteins.\
The figure shows linear, ssRNA (+) genome of \~ 7.2 kb HEV genome and corresponding viral proteins. The 5′-end is capped and the 3′-terminus is polyadenylated. ORF1 encodes the nonstructural polyprotein, including methyltransferase (Met), Y-domain (Y), papain-like cysteine protease (PCP), hypervariable region (HVR), macro-domain (X), RNA helicase (Hel) and RNA-dependent RNA polymerase (RdRp). ORF2 encodes the capsid protein (CP), containing S domain (S), M domain (M) and P domain (P). The glycosylation sites of ORF2 are indicated (Asn137, Asn310, and Asn562). ORF3 encodes a small multifunctional protein (MFP) including hydrophobic regions (D1, D2) and proline-rich regions (P1, P2). The phosphorylation site (Ser80) and the SH3-binding domain are indicated. ORF2 is translated by leaky scanning from the bicistronic ORF3-2 \~ 2.0 kb subgenomic RNA. JR is ORF2 and ORF3 overlapping/intergenic-junction region; CRE is *cis*-reactive element; SP is signal peptide. Nucleotide positions are relative to the HEV-1 Burmese strain (Acc. No. M73218)/HEV-3 47832 strain (Acc. No. KC618402). Asterisk (\*) indicates the hot spot region for clinical mutations (adapted from ([@bb0045], [@bb0060]).](gr1){#f0005}

![Effect of mutations on HEV replication cycle and clinical significance.\
Schematic description of the HEV replication cycle and effect of mutations occurring in the HEV genome (red boxes; domain and region are indicated) on the transcriptional/translational machinery (blue dotted box) of HEV. Asterisks (\*\*\*) indicate mutations described in the text. The possible effect of mutations on HEV replication is denoted at the side, described clinical outcome below the red boxes.](gr2){#f0010}

###### 

Artificial HEV mutations and their functional significance in the physiological activity and infectivity.

Table 1

  Substitution/mutation                                 Amino acid change                                               Domain/region   HEV genotype                        Functional significance                                                                                                  References
  ----------------------------------------------------- --------------------------------------------------------------- --------------- ----------------------------------- ------------------------------------------------------------------------------------------------------------------------ ---------------------------------
  NA                                                    H443L; C457A; C459A; C471A; C472A; C481A; C483A; H497L; H590L   PCP/OFR1        HEV-1                               Completely abolish HEV replication by modifying the enzyme structure                                                     [@bb0385]; [@bb0405]
  Insertion/deletion                                    NA                                                              HVR/ORF1        Human HEV-1 avian HEV swine HEV-3   Associated with HEV attenuation                                                                                          [@bb0440]
  Complete deletion                                     NA                                                              HVR/ORF1        avian HEV human HEV                 Abolish HEV infectivity but not influence HEV replication                                                                [@bb0445]
  Insertion/deletion of a 24 bp RdRp-derived fragment   NA                                                              HVR/ORF1        human HEV-3                         Decrease HEV replication                                                                                                 [@bb0095]
  NA                                                    N809A; H812L; G816A/V; G817A/V                                  X/OFR1          HEV-1                               Completely abolish HEV replication                                                                                       [@bb0385]; [@bb0390]
  NA                                                    L1110F; V1120I                                                  Hel/ORF1        Human HEV-1                         Decrease HEV replication by affecting the ATPase activity but not the RNA duplex unwinding activity of helicase enzyme   [@bb0100]
  Deletion                                              NA                                                              Hel/ORF1        NA                                  Decrease HEV replication impairing the ATPase and unwinding activities of helicase enzyme                                [@bb0335]
  NA                                                    K1383N                                                          RdRp/ORF1       HEV-3                               Reduces viral replication and increases ribavirin sensitivity                                                            [@bb0095]
  NA                                                    Y1320H; G1634R/K                                                RdRp/ORF1       HEV-1, HEV-3                        Increased efficiency of viral replication and infectivity                                                                [@bb0095]; [@bb0085]; [@bb0540]
  T5338C                                                F51L                                                            ORF2            Swine HEV                           Decrease HEV replication and infectivity by affecting viral genomic RNA packaging                                        [@bb0425]; [@bb0430]
  A5362G                                                T59A                                                            ORF2            Swine HEV                           Decrease HEV replication and infectivity by affecting viral genomic RNA packaging                                        [@bb0185]; [@bb0065]
  C6356T                                                S390L                                                           ORF2            Swine HEV                           Decrease HEV replication and infectivity by preventing host virus interaction                                            [@bb0425]; [@bb0430]
  NA                                                    N137Q; N310Q; N311Q                                             ORF2            NA                                  Prevent glycosylation of capsid protein and formation of HEV particles                                                   [@bb0165]
  NA                                                    N562Q/D/P/Y                                                     ORF2            NA                                  Affect the dimerization of ORF2 protein and HEV infectivity                                                              [@bb0165]
  NA                                                    L477T; L613T                                                    ORF2            HEV-4                               Influence immunoreactivity of HEV by affecting the neutralization epitope                                                [@bb0570]; [@bb0310]
  NA                                                    V606A                                                           ORF2            HEV-1                                                                                                                                                        
  A5145C; A5178C; A5190C; G5676T; T5690G                NA                                                              ORF2--ORF3      HEV-2                               Abolish the ORF2 production (but not ORF3)                                                                               [@bb0155]
  CGC5148--5150AGA                                      NA                                                              ORF2--ORF3      HEV-2                               Abolish ORF3 production (but not ORF2)                                                                                   [@bb0155]
  A5108Δ; T5109C; C5112U; TCT5116--5118AGC; T5121C      NA                                                              ORF2--ORF3      HEV-2                               Abolish both production of both ORF2 and ORF3                                                                            [@bb0155]
  NA                                                    S80A (V66G)                                                     ORF3 (ORF2)     NA                                  May affect the regulatory role of ORF3 protein in HEV assembly, influence ORF2--ORF3 interaction                         [@bb0545]; [@bb0155]
  G5101U; U5100C; C5117G; U5118G                        NA                                                              CRE/ORF3        HEV-2                               Affect HEV replication and infectivity by modifying the CRE structure                                                    [@bb0395]
  G6574C; C6570G; G7106T/A; G7097A; C7144A              NA                                                              CRE/ORF2        HEV-3                               Affect HEV replication and infectivity by modifying the CRE structure                                                    [@bb0115]; [@bb0120]; [@bb0160]

NA: not applicable.

###### 

HEV mutations detected in patient-derived isolates and their clinical relevance.

Table 2

  Nucleotide substitution   Amino acid change                Domain/region   HEV genotype              Associated clinical manifestation   Mechanism                                                   Reference
  ------------------------- -------------------------------- --------------- ------------------------- ----------------------------------- ----------------------------------------------------------- ---------------------------------
  C1816                     no                               ORF1            Clinical isolates HEV-4   Fulminant hepatitis failure         Unknown                                                     [@bb0195]; [@bb0200]
  U3148                     no                               ORF1                                                                                                                                      
  C5907                     no                               ORF2                                                                                                                                      
  186 bp insertion          no                               HVR/ORF1        Clinical isolates HEV-3   Chronic hepatitis                   Unknown                                                     [@bb0215]
  90 bp insertion           no                               HVR/ORF1        Clinical isolates HEV-3   Unknown                             Unknown                                                     [@bb0290]
  171 bp insertion          no                               HVR/ORF1        Clinical isolates HEV-3   Chronic hepatitis                   Efficient growth in cell culture                            [@bb0495]
  174 bp insertion          no                               HVR/ORF1        Clinical isolates HEV-3   Chronic hepatitis                   Cross-species infections                                    [@bb0495]
  117 bp insertion          no                               HVR/ORF1        Clinical isolates HEV-3   Chronic hepatitis                   Growth advantage in cell culture                            [@bb0380]
  a 282 bp-insertion        no                               HVR/ORF1        Clinical isolates HEV-3   Ribavirin treatment failure         Unknown                                                     [@bb0095]
  NA                        V239A                            Hel/ORF1        HEV-3                     More severe hepatitis               Enhance the helicase activity                               [@bb0530]
  T563C                     F179S                            MeT/ORF1        Clinical isolates HEV-1   Fulminant hepatic failure           Unknown                                                     [@bb0340]
  G977A                     A317T                            Y/ORF1                                                                                                                                    
  C2232T                    T735I                            HVR/ORF1                                                                                                                                  
  T3355C                    L1110F                           Hel/ORF1                                                                                                                                  
  G3386A                    V1120I                           Hel/ORF1                                                                                                                                  
  T4344A                    F1439Y                           RdRp/ORF1                                                                                                                                 
  C4476G; A4616C            C1483W; N1530T                   RdRp/ORF1       Clinical isolates HEV-1   Fulminant hepatic failure           Maybe enhance HEV replication?                              [@bb0030]
  C5927T                    NA                               ORF2            Clinical isolates HEV-1   Fulminant hepatic failure           Unknown                                                     [@bb0025]
  C5933T                    NA                               ORF2                                                                                                                                      
  T6014C                    NA                               ORF2                                                                                                                                      
  C6032T                    NA                               ORF2                                                                                                                                      
  G6098A                    NA                               ORF2                                                                                                                                      
  C6104T                    NA                               ORF2                                                                                                                                      
  NA                        P259S                            ORF2                                                                                                                                      
  NA                        Y1320H; G1634R/K                 RdRp/ORF1       Clinical isolates HEV-3   Ribavirin treatment failure         Increased efficiency of viral replication and infectivity   [@bb0095]; [@bb0085]; [@bb0540]
  NA                        K1383N                           RdRp/ORF1       Clinical isolates HEV-3   Ribavirin treatment failure         Unknown                                                     [@bb0095]; [@bb0540]
  NA                        D1384G; K1398R; V1479I; Y1587F   RdRp/ORF1       Clinical isolates HEV-3   Ribavirin treatment failure         Unknown                                                     [@bb0540]
  246 bp deletion           NA                               ORF3            Clinical strain           Unknown                             Unknown                                                     [@bb0460]

NA: not applicable.
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